Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation.

Cabozantinib is likely to be the best treatment to delay tumour growth and prolong life, followed by nivolumab, but all treatments delayed disease progression and prolonged survival compared with best supportive care.

http://ift.tt/2Bf2apW